{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:59:19Z","timestamp":1785833959569,"version":"3.56.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"34","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.vaccine.2017.06.083","type":"journal-article","created":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T20:00:39Z","timestamp":1499284839000},"page":"4315-4320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["A single center, open label study of intradermal administration of an inactivated purified chick embryo cell culture rabies virus vaccine in adults"],"prefix":"10.1016","volume":"35","author":[{"given":"Sergio","family":"Recuenco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Warnock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modupe O.V.","family":"Osinubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Rupprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.06.083_b0005","series-title":"The history of rabies","first-page":"1","author":"Baer","year":"2007"},{"issue":"RR-3","key":"10.1016\/j.vaccine.2017.06.083_b0010","first-page":"1","article-title":"Human rabies prevention--United States, 2008: recommendations of the advisory committee on immunization practices","volume":"57","author":"Manning","year":"2008","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2017.06.083_b0015","doi-asserted-by":"crossref","first-page":"e0003709","DOI":"10.1371\/journal.pntd.0003709","article-title":"Estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2017.06.083_b0020","doi-asserted-by":"crossref","first-page":"646","DOI":"10.2460\/javma.237.6.646","article-title":"Rabies surveillance in the United States during 2009","volume":"237","author":"Blanton","year":"2010","journal-title":"J Am Vet Med Assoc."},{"key":"10.1016\/j.vaccine.2017.06.083_b0025","unstructured":"CDC. Rabies vaccine supply is limited\u2013update as of August 22, 2008. Health alert network 2008 (cited 2009 6\/22\/2009); Available from: <http:\/\/www2a.cdc.gov\/HAN\/ArchiveSys\/ViewMsgV.asp?AlertNum=00277>."},{"key":"10.1016\/j.vaccine.2017.06.083_b0030","unstructured":"WHO, WHO Expert Consultation on Rabies. First report, in WHO technical report series No 931. 2004, WHO: Geneva. p. 121."},{"key":"10.1016\/j.vaccine.2017.06.083_b0035","unstructured":"WHO. WHO expert consultation on rabies: second report, in: WHO, editor. WHO technical report series. Geneva: World Health Organization; 2013. p. 139."},{"issue":"RR-3","key":"10.1016\/j.vaccine.2017.06.083_b0040","first-page":"1","article-title":"Human rabies prevention\u2013United States, 2008: recommendations of the advisory committee on immunization practices","volume":"57","author":"CDC","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2017.06.083_b0045","unstructured":"Centers for Disease, C., Recommendation of the immunization practices advisory committee (ACIP). Supplementary statement on pre-exposure rabies prophylaxis by the intradermal route. MMWR Morb Mortal Wkly Rep, 1982;31(21):279\u201380, 285."},{"issue":"5","key":"10.1016\/j.vaccine.2017.06.083_b0050","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4161\/hv.2.5.3197","article-title":"Comparison of saftey and immunogenicity of purified chick embryo cell rabies vaccine (PCECV) and purified vero cell rabies vaccine (PVRV) using the Thai Red Cross intradermal regimen at a dose of 0.1 ML","volume":"2","author":"Madhusudana","year":"2006","journal-title":"Hum Vaccin"},{"issue":"5","key":"10.1016\/j.vaccine.2017.06.083_b0055","first-page":"693","article-title":"Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine","volume":"78","author":"Briggs","year":"2000","journal-title":"Bull World Health Organ"},{"issue":"19","key":"10.1016\/j.vaccine.2017.06.083_b0060","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1016\/j.vaccine.2006.02.036","article-title":"Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen","volume":"24","author":"Ambrozaitis","year":"2006","journal-title":"Vaccine"},{"issue":"30","key":"10.1016\/j.vaccine.2017.06.083_b0065","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1016\/j.vaccine.2005.03.007","article-title":"Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine","volume":"23","author":"Beran","year":"2005","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2017.06.083_b0070","first-page":"639","article-title":"Intradermal simulated rabies postexposure prophylaxis using purified chick embryo rabies vaccine","volume":"75","author":"Charanasri","year":"1992","journal-title":"J Med Assoc Thai"},{"issue":"5","key":"10.1016\/j.vaccine.2017.06.083_b0075","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0264-410X(89)90152-7","article-title":"Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization","volume":"7","author":"Dreesen","year":"1989","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.083_b0080","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jpeds.2007.02.044","article-title":"Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe","volume":"151","author":"Kamoltham","year":"2007","journal-title":"J Pediatr"},{"issue":"14","key":"10.1016\/j.vaccine.2017.06.083_b0085","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.vaccine.2004.09.027","article-title":"Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1 ml PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals","volume":"23","author":"Quiambao","year":"2005","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2017.06.083_b0090","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4161\/hv.1.5.2110","article-title":"Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines. Results of a meta-analysis","volume":"1","author":"Sudarshan","year":"2005","journal-title":"Hum Vaccin"},{"issue":"6","key":"10.1016\/j.vaccine.2017.06.083_b0095","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/0264-410X(94)90308-5","article-title":"A simplified and economical intradermal regimen of purified chick embryo cell rabies vaccine for postexposure prophylaxis","volume":"12","author":"Suntharasamai","year":"1994","journal-title":"Vaccine"},{"issue":"8471","key":"10.1016\/j.vaccine.2017.06.083_b0100","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(86)91918-5","article-title":"Purified chick embryo cell rabies vaccine","volume":"1","author":"Wasi","year":"1986","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2017.06.083_b0105","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1708-8305.2007.00120.x","article-title":"Immunogenicity study of abbreviated rabies preexposure vaccination schedules","volume":"14","author":"Khawplod","year":"2007","journal-title":"J Travel Med"},{"issue":"13","key":"10.1016\/j.vaccine.2017.06.083_b0110","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.vaccine.2013.01.035","article-title":"Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis","volume":"31","author":"Wongsaroj","year":"2013","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.vaccine.2017.06.083_b0115","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1016\/j.vaccine.2011.12.028","article-title":"One clinic visit for pre-exposure rabies vaccination (a preliminary one year study)","volume":"30","author":"Khawplod","year":"2012","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2017.06.083_b0120","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.tmaid.2013.09.006","article-title":"Immunogenicity of a modified intradermal pre-exposure rabies vaccination schedule using a purified chick embryo cell vaccine: an observational study","volume":"11","author":"Lau","year":"2013","journal-title":"Travel Med Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2017.06.083_b0125","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.tmaid.2015.05.008","article-title":"Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine","volume":"13","author":"Jelinek","year":"2015","journal-title":"Travel Med Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2017.06.083_b0130","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1056\/NEJM198601303140504","article-title":"Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine","volume":"314","author":"Pappaioanou","year":"1986","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2017.06.083_b0135","first-page":"535","article-title":"A rapid reproducible test for determining rabies neutralizing antibody","volume":"48","author":"Smith","year":"1973","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2017.06.083_b0140","unstructured":"WHO, Human and dog rabies prevention and control. Report of the WHO\/Bill & Melinda Gates Foundation Consultation Annecy, France 7\u20139 October 2009; 2010. WHO\/HTM\/NTD\/\/NZD\/2010.1."},{"key":"10.1016\/j.vaccine.2017.06.083_b0145","doi-asserted-by":"crossref","first-page":"383870","DOI":"10.4061\/2011\/383870","article-title":"Human rabies in the WHO Southeast Asia region: forward steps for elimination","volume":"2011","author":"Gongal","year":"2011","journal-title":"Adv Prev Med"},{"issue":"3","key":"10.1016\/j.vaccine.2017.06.083_b0150","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2471\/BLT.16.173039","article-title":"Pre-exposure rabies prophylaxis: a systematic review","volume":"95","author":"Kessels","year":"2017","journal-title":"Bull World Health Organ"},{"issue":"21","key":"10.1016\/j.vaccine.2017.06.083_b0155","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1016\/j.vaccine.2007.02.075","article-title":"Safety review of the purified chick embryo cell rabies vaccine: data from the vaccine adverse event reporting system (VAERS), 1997\u20132005","volume":"25","author":"Dobardzic","year":"2007","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17308800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17308800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T19:27:35Z","timestamp":1537903655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17308800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":31,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0264410X17308800"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.06.083","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A single center, open label study of intradermal administration of an inactivated purified chick embryo cell culture rabies virus vaccine in adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.06.083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}